Molecular genetics diagnostic company Mainz Biomed N.V. (NASDAQ:MYNZ) said on Tuesday that it has applied to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its next-generation colorectal cancer (CRC) screening test.
The test has demonstrated 97% sensitivity for cancer and 88% for advanced adenomas, with high specificity.
This designation, if granted, could expedite approval for the test that combines the Fecal Immunochemical Test (FIT) with mRNA biomarkers and AI analysis.
CHMP backs Camurus' Oczyesa for acromegaly treatment in EU
Life Molecular Imaging's Neuraceq available at PharmaLogic Salt Lake City
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
Coologics' seed funding round raises over USD3m
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
Renalytix reports real-world impact of KidneyIntelX on targeted kidney disease treatment
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Halozyme Therapeutics' VYVGART Hytrulo prefilled syringe for self-injection receives US FDA approval